18 and older, any sex, with Granulomatosis With Polyangiitis or Microscopic Polyangiitis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Patients to Achieve Both Complete Remission and Seronegativity for ANCA.Primary· 6 months
Complete remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0 without glucocorticoids beyond the prescribed prednisone taper. Seronegativity for ANCA is defined as a negative test for antibodies directed against serine proteinase 3 (i.e., a negative PR3-ANCA assay).
Group
Value
95% CI
Intravenous Dose of Obinutuzumab
0
Intravenous Dose of Rituximab
0
Number of Patients to Achieve Sustained Complete Remission 6 MonthsSecondary· 6 months
Complete remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0 without glucocorticoids beyond the prescribed prednisone taper.
Group
Value
95% CI
Intravenous Dose of Obinutuzumab
1
Intravenous Dose of Rituximab
0
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse Events were collected from baseline to end of study for a total of approximately eighteen months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07003295 — Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease R
· Phase 2
· recruiting
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g
· Phase 2
· not yet recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal
· Phase 2
· recruiting
NCT07480850 — Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
· Phase 2
· active not recruiting
NCT07261163 — Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
· Phase 2
· not yet recruiting
Other recruiting trials for Granulomatosis With Polyangiitis
Currently open trials in the same condition.
NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
· Phase 4
· recruiting
NCT03919435 — TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
· Phase 1, PHASE2
· active not recruiting
NCT01933724 — The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
· Phase 3
· active not recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men
· NA
· not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
· not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance,
· NA
· not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)
· NA
· recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 31 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05376319.